Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients;Impacto de la carga vírica inicial de citomegalovirus sobre la eficacia del tratamiento anticipado con ganciclovir en receptores de trasplante de progenitores hematopoyéticos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 1, 2010, Pages 6-12

  Torre Cisneros, Julián ^a   Caston Osorio, Juan José ^a   Martín, Carmen ^a   Rivero, Antonio ^a   Doblas, Antonio ^a   Rojas, Rafael ^a   Gómez, Pedro ^a   Martínez, Francisco ^a   Torres, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cytomegalovirus; Ganciclovir; Preemptive therapy; Stem cell transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GANCICLOVIR; IMMUNOGLOBULIN ANTIBODY; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; OFLOXACIN; PREDNISONE; STEROID; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROPHYLAXIS; RADIATION DOSE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEUTROPENIA; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA; VIRUS ACTIVATION; VIRUS REPLICATION; YOUNG ADULT;

EID: 73249132038     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.01.010     Document Type: Article

References (19)

1. Ljungman P., Reusser P., De la Camara R., Einsele H., Engelhard D., Ribaud P., et al. Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33 (2004) 1075-1081
2. Avery R.K., Adal K.A., Longworth D.L., and Bolwell B.J. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 26 (2000) 763-767
3. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., and Cordonnier C. Donor CMV serological status and outcome of CMV seropositive recipients after unrelated donor stem cell transplantation: An EBMT Megafile analysis. Blood 102 (2003) 4255-4260
4. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., and Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355 (2000) 2032-2036
5. Herrera C., Torres A., García-Castellano J.M., Roman J., Martin C., Serrano J., et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant 23 (1999) 443-450
6. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
7. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
8. Boivin G., Gilbert C., Gaudreau A., Greenfield I., Sudlow R., and Roberts N.A. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 184 (2001) 1598-1602
9. Butt N., and Clark R. High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allografts recipients at low risk of CMV. Bone Marrow Transplant 27 (2001) 615-619
10. Qamruddin A.O., Oppenheim B.A., Guiver M., Mutton K.J., and Chopra R. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: Analysis of potential risk factors for CMV infection. Bone Marrow Transplant 27 (2001) 301-306
11. Lilleri D., Baldanti F., Gatti M., Rovida F., Dossena L., De Grazia S., et al. Clinically-based determination of safe DNAemia cutoff levels for pre-emptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 73 (2004) 412-418
12. Verkruyse L.A., Storch G.A., Devine S.M., DiPersio J.F., and Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ≥10 000 copies/ml: A safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 37 (2006) 51-56
13. Yanada M., Yamamoto K., Emi N., Naoe T., Suzuki R., Taji H., et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: Retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 32 (2003) 801-807
14. Ljungman P., Aschan J., Lewensohn-Fuchs I., Carlens S., Larsson K., Lonnqvist B., et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66 (1998) 1330-1334
15. Junghanss C., Boeckh M., Carter R.A., Sandmaier B.M., Maris M.B., and Maloney D.G. Incidence and outcome of cytomegalovirus infections following myeloablative compared with myeloablative allogeneic stem cell transplantation. Blood 99 (2002) 1978-1985
16. Hebart H., Brugger W., Grigileit U., Gscheidle B., Loeffler J., Schäfer H., et al. Risk of cytomegalovirus disease in patients receiving polymerase chain reaction-based pre-emptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 97 (2001) 2183-2185
17. Herenstein B., Hampl W., Bunjes D., Wiesneth M., Duncker C., Koszinowski U., et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 15 (1995) 387-393
18. Emery V.C. Viral dynamics during active cytomegalovirus infection and pathology. Intervirology 42 (1999) 405-411
19. Torre-Cisneros J., Roman J., Torres A., Herrera C., Caston J.J., Rivero A., et al. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation. J Infect Dis 190 (2004) 1596-1599